Early rhythm control in patients with acute decompensated heart failure: results from the CYCLE cohort study.
Marvin Kriz, Caroline Kellner, Benedikt N Beer...
https://pubmed.ncbi.nlm.nih.gov/41342526Actively Recruiting
Age: 18Years +
All Genders
ID07508891
Characterisation of phenotYpes in aCute Heart faiLure patiEnts
Led by Universitätsklinikum Hamburg-Eppendorf · Updated on 2026-04-02
1000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to better understand different groups of patients with acute heart failure, including those experiencing various stages of cardiogenic shock. The study focuses on identifying functional, imaging, and blood biomarkers that could help predict outcomes for these patients and assist in designing future clinical trials. It is a prospective, single-center observational cohort study involving patients hospitalized for acute heart failure. Participants in this study will be observed without receiving any experimental treatment. The research will collect data on functional parameters, radiological imaging, and blood samples for biomarker analysis, including biobanking for future studies. The study includes all stages of acute heart failure and cardiogenic shock, enrolling patients during their hospital stay. During participation, patients will be monitored from enrollment up to 5 years to assess the time to cardiovascular death or first rehospitalization for heart failure. Additional outcomes include rates of rehospitalizations, progression of cardiogenic shock, severe bleeding, renal replacement therapy, ischemic events, and brain injury diagnosis assessed at discharge. The study involves regular evaluations and long-term follow-up to improve risk prediction and patient care strategies.
CONDITIONS
Brief Title
Characterisation of phenotYpes in aCute Heart faiLure patiEnts
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis of acute heart failure, including all stages of cardiogenic shock, de novo heart failure as well as decompensated chronic heart failure.
- Hospitalisation due to acute heart failure or new-onset acute heart failure during a hospitalisation due to a different cause.
- Age 18 years or older.
- Written informed consent provided.
You will not qualify if you...
- Age under 18 years.
- No written informed consent.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Monitoring
Duration - Up to 5 years
Participants are observed to identify functional, radiological, and circulating biomarkers related to acute heart failure and cardiogenic shock.
Regular assessments during hospitalization and follow-up visits over 5 years
Trial Site Locations
Total: 1 location
1
University Medical Center Hamburg-Eppendorf
Hamburg, Germany, 20246
Actively Recruiting
Loading map...
Research Team
B
Benedikt Schrage, MD, PhD
C
Christina Magnussen, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Pro-adrenomedullin associates with congestion in acute heart failure patients.
Benedikt N Beer, Saman Keshtkaran, Caroline Kellner...
https://pubmed.ncbi.nlm.nih.gov/39161275Prediction of cardiac worsening through to cardiogenic shock in patients with acute heart failure.
Benedikt N Beer, Caroline Kellner, Jonas Sundermeyer...
https://pubmed.ncbi.nlm.nih.gov/38632837